Prognostic impact of race and ethnicity in the treatment of colorectal cancer.
Numerous advances in the treatment of patients who have metastatic disease have improved colorectal cancer management, including new chemotherapeutic agents and combinations and targeted agents that modulate the efficacy of chemotherapy. Recent advances in the administration of irinotecan and oxaliplatin, in combination with 5-FU/LV, plus the addition of targeted agents bevacizumab and cetuximab have afforded steady increases in response rates and survival. Ongoing studies are evaluating the optimal sequencing and combinations of the agents described and the efficacy of new combinations in metastatic and adjuvant settings. Because the number of African-American patients in most clinical trials in colorectal cancer has been low, it is imperative that method increase participation so that new research developments reach all segments of the population.
Mitchell
Edith P
EP
Division of Medical Oncology, Kimmel Cancer Center, Thomas Jefferson University, Gibbon Building, Suite 4240, Philadelphia, PA 19107, USA. edith.mitchell@jefferson.edu
D001741:Black or African American; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000208:ethnology* / Q000473:pathology; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy / Q000208:ethnology / Q000556:secondary; D018426:SEER Program; D015996:Survival Rate; D014481:United States / Q000453:epidemiology